cigna glp 1 2025 requirements doubles down on GLP-1 support programs with 2 new launches GLP-1 Pipeline Update: May 2025

Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P

As with any supplement, all glutathione supplements are not created equal

Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models

10.1016/j.scitotenv.2020.140429 17 ElshaghabeeF

70 Potentially Higher Intakes: For athletes or individuals in significant energy deficits, recommendations can range even higher, sometimes up to 2.0-2.4 g/kg/day